Correlation Between Lipella Pharmaceuticals and Cingulate

Can any of the company-specific risk be diversified away by investing in both Lipella Pharmaceuticals and Cingulate at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lipella Pharmaceuticals and Cingulate into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lipella Pharmaceuticals Common and Cingulate, you can compare the effects of market volatilities on Lipella Pharmaceuticals and Cingulate and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lipella Pharmaceuticals with a short position of Cingulate. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lipella Pharmaceuticals and Cingulate.

Diversification Opportunities for Lipella Pharmaceuticals and Cingulate

0.4

Correlation Coefficient

Lipella Pharmaceuticals  Cingulate

Very weak diversification

The 3 months correlation between Lipella and Cingulate is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Lipella Pharmaceuticals Common and Cingulate in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cingulate and Lipella Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lipella Pharmaceuticals Common are associated (or correlated) with Cingulate. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cingulate has no effect on the direction of Lipella Pharmaceuticals i.e., Lipella Pharmaceuticals and Cingulate go up and down completely randomly.

Pair Corralation between Lipella Pharmaceuticals and Cingulate

Given the investment horizon of 90 days Lipella Pharmaceuticals Common is expected to generate 1.23 times more return on investment than Cingulate. However, Lipella Pharmaceuticals is 1.23 times more volatile than Cingulate. It trades about 0.02 of its potential returns per unit of risk. Cingulate is currently generating about -0.08 per unit of risk. If you would invest  332.00  in Lipella Pharmaceuticals Common on August 31, 2024 and sell it today you would lose (21.00) from holding Lipella Pharmaceuticals Common or give up 6.33% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Lipella Pharmaceuticals Common  vs.  Cingulate

Lipella Pharmaceuticals

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lipella Pharmaceuticals Common are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Lipella Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Cingulate

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cingulate has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with Lipella Pharmaceuticals and Cingulate

The main advantage of trading using opposite Lipella Pharmaceuticals and Cingulate positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lipella Pharmaceuticals position performs unexpectedly, Cingulate can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cingulate will offset losses from the drop in Cingulate's long position.

The idea behind Lipella Pharmaceuticals Common and Cingulate pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.